Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 3Endocrine 3Genitourinary 2Thoracic 1Sarcoma 1Head & Neck 1Gynecologic 1Gastrointestinal 1CNS 1Breast 1

Conditions

Ovarian Neoplasms 20Uterine Cervical Neoplasms 19Endometrial Neoplasms 9Stomach Neoplasms 8Melanoma 8Carcinoma, Renal Cell 8Squamous Cell Carcinoma of Head and Neck 7Colorectal Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Fallopian Tube Neoplasms 6Carcinoma, Hepatocellular 6Breast Neoplasms 6Pancreatic Neoplasms 5Carcinoma, Transitional Cell 5Triple Negative Breast Neoplasms 4Neoplasms 4Neoplasm Metastasis 4Head and Neck Neoplasms 4Esophageal Neoplasms 4Carcinoma, Merkel Cell 4Small Cell Lung Carcinoma 3Prostatic Neoplasms 3Sarcoma 2Recurrence 2Microsatellite Instability 2Lymphoma 2Kidney Neoplasms 2Carcinoma, Squamous Cell 2Carcinoma 2Vulvar Neoplasms 1

Interventions

pembrolizumab 2Magnetic Resonance Spectroscopy 2Irinotecan 2Fluorodeoxyglucose F18 2FAPI-46 2tivozanib 1taxane 1liposomal doxorubicin 1fludarabine 1entrectinib 1atezolizumab 1alectinib 1aldesleukin 1Vinorelbine 1RRx-001 1Quality of Life 1Pemetrexed 1Patient Reported Outcome Measures 1Paclitaxel 1PM 01183 1Nivolumab 1Molecular Diagnostic Techniques 1Immunotherapy 1Gemcitabine 1Etoposide 1Drug Therapy 1Cyclophosphamide 1Cisplatin 1Carboplatin 1Biological Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroendocrine Tumors × atezolizumab × Gynecologic × Clear all
NCT05000294 2026-06-05

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

University of Florida

Phase 1/2 Recruiting
29 enrolled
BreastEndocrineGastrointestinalGenitourinaryGynecologicNETSarcoma

Bile Duct Neoplasms, Breast Neoplasms, Gallbladder Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Vulvar Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡